Sign in to fuzzto save your conversations, follow your research and come back anytime.
Neuland Laboratories
SectorHealthcare
In the news
Neuland Labs Commissions First Peptide Module Despite Stock Drop
26 NIFTY500 stocks show 50%+ profit growth in Q1FY27
Neuland Laboratories profit surges 962% to ₹148 crore, shares jump 8%
Neuland Labs hits record ₹19,800 high, launches commercial peptide facility
6 Midcap Stocks Show Strong Q4 Performance Amid Mixed Earnings
HSBC, Jefferies, Goldman Sachs Issue Stock Recommendations for May 15
Neuland Laboratories shares surge 7% on 660% profit jump, Goldman Sachs raises target
Neuland Labs Q4 profit surges 7x to ₹213 crore on export orders
The Quarter story
The two most recent quarterly results, compared side-by-side.
Neuland Laboratories pivots to high-margin development projects, driving strong profitability and cash generation despite a sharp drop in commercial revenue.
Development revenue grows from ₹14 Cr to ₹418 Cr from Q1 FY26 to Q1 2026-27, highlighting a successful pipeline push.
Commercial revenue falls from ₹488 Cr to ₹20 Cr from Q4 FY26 to Q1 2026-27, signaling a temporary disruption in mature product sales.
EBITDA margin rises from 14% to 35.5% from Q1 FY26 to Q1 2026-27, confirming strong pricing power.
Specialty revenue mix drops from 44% to 8% from Q1 FY26 to Q1 2026-27, indicating a major shift away from this segment.
Working capital days of sale fall from 145 days to 84 days from Q1 FY26 to Q1 2026-27, showing faster cash conversion.
Top 5 products concentration rises from 85% to 89% from Q1 FY26 to Q1 2026-27, keeping product focus narrow.
Top 5 customer concentration drops from 47% to 40% from Q1 FY26 to Q1 2026-27, reducing client dependency.
Prime revenue mix declines from 32% to 18% from Q1 FY26 to Q1 2026-27, showing reduced contribution from this category.
ROCE improves from 5.1% to 35.8% from Q1 FY26 to Q1 2026-27, reflecting much better capital efficiency.